Want to see SG:42C full AI Analyst Report?
iX Biopharma Ltd. (42C) Financial Statements
iX Biopharma Ltd. Financial Overview
iX Biopharma Ltd.'s market cap is currently $558.96M. The company's EPS TTM is $-0.01; its P/E ratio is -61.45; iX Biopharma Ltd. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 6.85M | $ 7.77M | $ 5.96M | $ 5.91M | $ 14.39M |
| Gross Profit | $ 2.43M | $ 2.04M | $ 1.05M | $ 2.32M | $ 12.29M |
| Operating Income | $ -9.56M | $ -6.29M | $ -7.39M | $ -8.41M | $ 1.24M |
| EBITDA | $ -8.83M | $ -8.96M | $ -8.68M | $ -8.51M | $ -2.84M |
| Net Income | $ -7.99M | $ -10.14M | $ -10.79M | $ -9.62M | $ -4.60M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 14.73M | $ 866.00K | $ 1.77M | $ 6.52M | $ 13.49M |
| Total Assets | $ 25.88M | $ 11.28M | $ 14.62M | $ 24.93M | $ 28.52M |
| Total Debt | $ 5.80M | $ 5.90M | $ 5.20M | $ 4.34M | $ 4.41M |
| Net Debt | $ -8.93M | $ 5.04M | $ 3.43M | $ -2.18M | $ -9.09M |
| Total Liabilities | $ 10.48M | $ 10.92M | $ 10.28M | $ 9.08M | $ 8.77M |
| Stockholders' Equity | $ 15.40M | $ 365.00K | $ 4.34M | $ 15.85M | $ 19.74M |
| Cash Flow | |||||
| Free Cash Flow | $ -8.07M | $ -3.96M | $ -6.84M | $ -8.36M | $ 2.92M |
| Operating Cash Flow | $ -7.96M | $ -3.76M | $ -6.55M | $ -7.66M | $ 3.12M |
| Investing Cash Flow | $ -117.00K | $ -201.00K | $ 1.06M | $ -695.00K | $ -5.62M |
| Financing Cash Flow | $ 21.93M | $ 3.12M | $ 724.00K | $ 1.42M | $ 9.79M |
Currency in SGD
